Cidara Therapeutics (NASDAQ:CDTX) and Acorda Therapeutics (NASDAQ:ACOR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership.
Earnings & Valuation
This table compares Cidara Therapeutics and Acorda Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cidara Therapeutics||N/A||N/A||-$55.72 million||($3.18)||-1.27|
|Acorda Therapeutics||$588.29 million||1.61||-$223.35 million||$1.04||19.18|
Cidara Therapeutics has higher earnings, but lower revenue than Acorda Therapeutics. Cidara Therapeutics is trading at a lower price-to-earnings ratio than Acorda Therapeutics, indicating that it is currently the more affordable of the two stocks.
This table compares Cidara Therapeutics and Acorda Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
68.3% of Cidara Therapeutics shares are held by institutional investors. 15.2% of Cidara Therapeutics shares are held by company insiders. Comparatively, 7.8% of Acorda Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a summary of recent ratings and price targets for Cidara Therapeutics and Acorda Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cidara Therapeutics currently has a consensus price target of $12.33, indicating a potential upside of 205.28%. Acorda Therapeutics has a consensus price target of $23.09, indicating a potential upside of 15.74%. Given Cidara Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Cidara Therapeutics is more favorable than Acorda Therapeutics.
Risk & Volatility
Cidara Therapeutics has a beta of 1.84, meaning that its share price is 84% more volatile than the S&P 500. Comparatively, Acorda Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500.
Cidara Therapeutics beats Acorda Therapeutics on 8 of the 13 factors compared between the two stocks.
About Cidara Therapeutics
Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. It is also developing antibody-drug conjugates for multidrug-resistant bacterial infections that directly kill pathogens and also direct a patient's immune system to attack and eliminate bacterial, fungal, or viral pathogens. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
About Acorda Therapeutics
Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women's Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.